Industry: Biotech
Biotech startup funding
In biotech, each round pays for one proof point, and investors price the risk left after it. Waveup prepares the materials that make that case: deck, model, valuation and investor list.
- Investor types and 2026 funding data for drug, platform and techbio startups
- Decks and models built around data readouts and partner deals
- Waveup prepares investor materials for biotech companies: $3B+ raised for 600+ startups since 2014
In short
What is biotech startup funding?
Biotech startup funding is the money drug, platform and techbio companies raise to reach their next scientific proof point. It comes from grants, angels, company builders, specialist funds, pharma venture arms and lenders. Biotech startups raised more than $9.1B of venture money in the first half of 2026. Investors favour companies with a drug already in human trials.
- Who it's for
- Therapeutics, platform and techbio startups, pre-seed to Series D+
- What we build
- Investor deck, financial model, valuation, investor list, data room
- Prices
- Deck from $6,000, model from $3,000. Flat fees
- Track record
- $3B+ raised for 600+ startups since 2014
Market data checked on 6 November 2026. Sources are under each section.
Is biotech startup funding improving in 2026?
For companies with human data, yes. New companies built on early science still struggle to close a first round.
The opportunity
Big drugmakers need new medicines, and they buy many of them from startups.
- Most late-stage drugs at the largest drugmakers now come from outside
- Buyers often acquire companies before they have clinical data
- AI is drawing new investors into health and biotech, including tech companies
The problem
Biotech is getting a smaller slice of venture money. Less than 9% of US startup funding went to biotech companies in 2025.
Market size
Why do big drugmakers need biotech startups?
Large drugmakers buy many of their future medicines from young companies. Acquirers agreed to pay more than $38B for venture-backed biotechs in 2024 and 2025. Four forces keep that demand high:
- Outside sourcing: 61% of late-stage drugs at the 20 biggest R&D spenders came from outside in 2025
- Rising costs: one new drug cost $2.67B to develop in 2025, from discovery to launch
- Obesity drugs: without GLP-1 and GIP drugs, big pharma's forecast R&D return was just 2.9% in 2025
- Early buyouts: half or more of private biopharma M&A targets are preclinical or in Phase I
Venture capital
Where is biotech venture money going in 2026?
Biotech venture money rose in the first half of 2026, carried by megarounds. First financings for new companies were $1.2B in Q1, tied for the lowest quarter since 2024.
raised by venture-backed biotech startups in the first half of 2026, the highest first half since 2022
of that money came in megarounds of $100M or more
raised by AI drug discovery company Isomorphic Labs in the first half of 2026
Who invests in biotech startups?
Company builders, specialist biotech funds, healthcare investors, pharma venture arms, lenders and state agencies. Each row is one example of a type; our guide to VCs investing in life sciences names many more.
Investor database
Biotech investors in our database
The funds with the most biotech investments. Pick a stage, or open a fund for its cheque sizes.
Top 5 by biotech investments
Investments by industry
- Healthtech & Wellness47%
- Biotech26%
- Pharma20%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- Chicago, United States
- Invests in
- USA
502 investments in total, 23 tagged Biotech.Open the full fund profile
Investments by industry
- Healthtech & Wellness41%
- Biotech36%
- Pharma18%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- Boston, United States
- Invests in
- USA
141 investments in total, 22 tagged Biotech.Open the full fund profile
Investments by industry
- Healthtech & Wellness38%
- Biotech33%
- Pharma17%
- Rounds
- SeedSeries ASeries C+
- Average cheque
- $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- San Francisco, United States
- Invests in
- USA
196 investments in total, 20 tagged Biotech.Open the full fund profile
Investments by industry
- Healthtech & Wellness44%
- Biotech27%
- Pharma15%
- Rounds
- Series ASeries BSeries C+
- Average cheque
- Not listed
- Based in
- Boston, United States
439 investments in total, 18 tagged Biotech.Open the full fund profile
Investments by industry
- Healthtech & Wellness46%
- Biotech25%
- Pharma16%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- Not listed
- Based in
- United States
- Invests in
- Israel, Europe, USA +1
231 investments in total, 17 tagged Biotech.Open the full fund profile
From our investor database.
What makes a biotech round hard to close?
We asked 56 VCs why they say no for our Fundraising 2025 study. Revenue growth, unit economics, burn and missed milestones topped the list. Defensibility and crowded categories came next. Before revenue, a biotech is judged on burn and milestones.
Investors want human data
Investors now favour drugs that are already being tested in people. About two in three rounds in the first half of 2026 went to companies with a drug in human testing.
What investors ask
- When will you have human data, and what will it show?
What your deck shows
- The first trial: design, endpoint and date
- What a positive readout does to your value
Few first rounds
First financings fell to $1.2B in Q1 2026, tied for the lowest quarter since 2024. Some money that once backed seed-stage science now funds companies built on licensed drugs from China or elsewhere.
What investors ask
- Why back your science instead of a licensed drug with data?
What your deck shows
- What your science can do that a licensed molecule can't
- A lead program with a short path to the clinic
Platforms must produce drugs
Computational biology companies took three of the ten largest biopharma rounds in Q1 2026. Most of their larger deals now include a drug in clinical testing.
What investors ask
- Which drug has your platform made, and when will it enter trials?
What your deck shows
- One lead program the platform produced
- Partner deals that pay for the platform
Cash runs out between readouts
Even biotechs that raised $50M or more can stall between rounds. In late 2025, Crunchbase counted over 200 private US biotechs in that position.
What investors ask
- Does this round reach a result that changes your value?
What your deck shows
- Months of cash left after the readout
- A fallback plan if the data slip
How we help you raise
Flat fees agreed before we start. No success fee on advisory work.
Mechanism, first patients and next readout, in plain words.
Trial budgets, cash runway and partnering scenarios, month by month.
Risk-adjusted value per program, checked against recent deals.
Company builders, biotech funds, pharma venture arms and lenders for your stage.
Patents, lab data and trial files, ordered for scientific review.
For a sale to a drugmaker, or a buyer's diligence questions.
Who we are
Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups. Biotech and pharma are the largest group among our 54+ deep-tech projects.
About usBiotech startup funding FAQ
How do biotech startups get funding?
How much venture capital goes into biotech in 2026?
What do investors look for in a biotech startup?
Can a biotech startup get grants instead of equity?
Who buys biotech startups, and for how much?
How much does help with a biotech raise cost?
Raising for a biotech company?
Tell us about your lead program and your next readout. We'll tell you how investors are likely to read your round.

